Navigation Links
Fovea Pharmaceuticals Completes EUR30M Series B Financing
Date:12/12/2007

Top venture syndicate invests to advance expanding pipeline of products to

treat ophthalmic diseases

PARIS, Dec. 12 /PRNewswire/ -- Fovea Pharmaceuticals SA, a biopharmaceutical company developing novel therapeutics for the treatment of ophthalmic diseases announced today that it raised EUR30M ($44M) in a Series B financing from a strong, international syndicate of new and existing investors led by Forbion Capital Partners (Naarden, The Netherlands). All existing institutional investors participated in the round including Sofinnova Partners, Abingworth, GIMV, The Wellcome Trust and CAPE.

Fovea plans to use the proceeds from this financing to advance its clinical and preclinical pipeline and further develop its technology platform. In 2008, Fovea expects to advance its FOV1101 program for chronic allergic conjunctivitis into phase 2 clinical trials and to initiate phase 2 studies of its FOV2302 and FOV2301 programs for the treatment of respectively acute and diabetic macular edema. The company expects to bring its fourth drug candidate, FOV2501, a protein discovered by Pr Jose-Alain Sahel's team (Inserm-UPMC U 592), into clinical trials in the first half of 2009.

"We are pleased that these leading investment firms recognize the value of Fovea's well balanced pipeline and unparalleled expertise in developing these novel therapies," said Bernard GILLY, Ph.D., Chairman and Chief Executive Officer of Fovea Pharmaceuticals. "The company has made enormous progress and this financing will enable us to continue to advance our lead programs through later-stage clinical studies."

"Forbion Capital Partners invests in biopharmaceutical companies pursuing first or best in class drugs. In particular, we focus on companies with strong domain expertise and experienced management. Fovea in our view is well positioned to become a leader in the ophthalmology field. We are impressed by how quickly they have built a highly promis
'/>"/>

SOURCE Fovea Pharmaceuticals SA.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure ... for those affected worldwide, will host its annual Crystal ... in Warrington, Pa. , Each year, the Crystal ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... has initiated coverage of Alliqua, Inc. (OTCQB: ALQA). ... manufacturing, and marketing proprietary products to serve the ... http://equitiesiq.com/reports/alliqua/ , In late 2012, Alliqua was ... which launched the company’s new strategy to become ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation ... discovering, developing and commercializing innovative therapies addressing ... today announced that it received the Notice ... and Trademark Office on its unique self-delivering ... fibrosis. The patent covers the use of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 During the ... is now known as “The Doctor’s Plague.” In this ... to wash their hands. This led, at times, to ... medical interns and hospital staff today don’t know that ... patients. The CBCD explains. , A study showed that ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... 23, 2011 Novavax, Inc. (Nasdaq: NVAX ) ... results in a press release to be issued after 8:00 ... hold an investor conference call at 10:00 a.m. The call ... Dr. Rahul Singhvi and other members of senior management. The ...
... SA , a Swiss-based biotechnology company with technologies for ... stable mammalian cell lines for therapeutic ... sequencing of their proprietary Chinese hamster ovary (CHO) cell ... performed in collaboration with the Institute of Biotechnology ...
... MARLBOROUGH, Mass., March 23, 2011 Advanced Cell Technology, ... a leader in the field of regenerative medicine, announced ... allowed the Company,s patent application to provide broad intellectual ... preparations of retinal pigment epithelial (RPE) cells from human ...
Cached Biology Technology:Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 2Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 3Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 4ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 2ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 3
(Date:4/15/2014)... Center in Greenbelt, Md., is home to hundreds ... At Goddard, some of the most cutting-edge Earth ... of that cutting-edge innovation has earned a Goddard ... Society for Anthropology and Geography awards the Vega ... has shown excellence in the fields of physical ...
(Date:4/15/2014)... study of nearly 1,000 mother-child pairs, researchers from ... prenatal exposure to selective serotonin reuptake inhibitors (SSRIs), ... other disorders, was associated with autism spectrum disorder ... study, published in the online edition of ... ASD and DD cases, and population-based controls, where ...
(Date:4/15/2014)... University of Missouri researchers have previously shown that a ... exercise exists. In a new study, Frank Booth, a ... found a potential link between the genetic pre-disposition for ... which mental maturation occurs. , For his study, Booth ... activity or extreme laziness. Booth then put the rats ...
Breaking Biology News(10 mins):Goddard scientist receives Vega Medal from King of Sweden 2Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2Genetic pre-disposition toward exercise and mental development may be linked 2
... (Jan. 28, 2009) Virginia Commonwealth University researchers have ... in regulating mitochondria, the energy-producing machines of cells. This ... new treatments for heart disease to boost energy in ... of cancer. In the study, published online Jan. ...
... available in French . MONTREAL, ... to announce that Concordia,s Centre for Structural and Functional ... by nine universities which are part of the Cellulosic ... the conversion of agricultural waste into biofuel is being ...
... This release is available in German . ... year as a result of pneumococcal infection, which causes ... and the elderly are especially at risk. Vaccines are ... and increasing resistance to antibiotics is making treatment more ...
Cached Biology News:Deceiving cell walls 2
... SpeedVac Model SPD131DDA , Our most chemically ... designed to handle the rigors and solvents of ... digital display, dual independent timers, an automatic bleeder ... vapor pathway. , , Adjustable Vacuum Level ...
...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
Biology Products: